Exelixis, Inc. (EX9.F)
- Previous Close
19.85 - Open
20.00 - Bid 19.83 x 90000
- Ask 19.99 x 90000
- Day's Range
20.00 - 20.00 - 52 Week Range
17.00 - 22.00 - Volume
20 - Avg. Volume
62 - Market Cap (intraday)
5.826B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
33.33 - EPS (TTM)
0.60 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.83
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
www.exelixis.comRecent News: EX9.F
Performance Overview: EX9.F
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EX9.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EX9.F
Valuation Measures
Market Cap
5.77B
Enterprise Value
5.07B
Trailing P/E
33.17
Forward P/E
16.72
PEG Ratio (5yr expected)
1.59
Price/Sales (ttm)
3.69
Price/Book (mrq)
2.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
11.10%
Return on Assets (ttm)
4.30%
Return on Equity (ttm)
8.76%
Revenue (ttm)
1.85B
Net Income Avi to Common (ttm)
205.05M
Diluted EPS (ttm)
0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
963.26M
Total Debt/Equity (mrq)
9.47%
Levered Free Cash Flow (ttm)
169.85M
Research Analysis: EX9.F
Company Insights: EX9.F
EX9.F does not have Company Insights